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Abstract
Background: There is an urgent need for the discovery and development of new drugs against Mycobacterium tuberculosis,
the causative agent of tuberculosis, especially due to the recent emergence of multi-drug and extensively-drug resistant
strains. Herein, we have examined the susceptibility of mycobacteria to the natural product platensimycin.
Methods and Findings: We have demonstrated that platensimycin has bacteriostatic activity against the fast growing
Mycobacterium smegmatis (MIC = 14 mg/ml) and against Mycobacterium tuberculosis (MIC = 12 mg/ml). Growth in the
presence of paltensimycin specifically inhibited the biosynthesis of mycolic acids suggesting that the antibiotic targeted the
components of the mycolate biosynthesis complex. Given the inhibitory activity of platensimycin against b-ketoacyl-ACP
synthases from Staphylococcus aureus, M. tuberculosis KasA, KasB or FabH were overexpressed in M. smegmatis to establish
whether these mycobacterial KAS enzymes were targets of platensimycin. In M. smegmatis overexpression of kasA or kasB
increased the MIC of the strains from 14 mg/ml, to 30 and 124 mg/ml respectively. However, overexpression of fabH on did
not affect the MIC. Additionally, consistent with the overexpression data, in vitro assays using purified proteins
demonstrated that platensimycin inhibited Mt-KasA and Mt-KasB, but not Mt-FabH.
Significance: Our results have shown that platensimycin is active against mycobacterial KasA and KasB and is thus an
exciting lead compound against M. tuberculosis and the development of new synthetic analogues.
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Introduction
Platensimycin (Figure 1A) is a secondary metabolite from
Streptomyces platensis [1,2,3] which has been shown to possess
potent anti-microbial activity against Gram-positive bacteria
including methicillin-resistant Staphylococcus aureus (MRSA) and
vancomycin-resistant Enterococci (VRE). The low mammalian cell
toxicity and the lack of antifungal activity indicates that
platensimycin acts selectively [3]. As a result platensimycin
represents a promising new chemical class of antibiotics with in
vivo activities of approximately 1 mg/ml towards S. aureus,
Enterococcus faecalis and Streptococcus pneumoniae [3]. Platensimycin
targets fatty acid biosynthesis in these species by inhibiting FabF
and FabH, two b-ketoacyl-ACP synthases (KAS) of the bacterial
multienzyme fatty acid synthase complex FAS-II [2,3]. Mycobac-
terium tuberculosis, the causative agent of tuberculosis contains three
distinct b-ketoacyl-ACP synthases, KasA, KasB and FabH [4,5].
Of these, FabH acts as a pivotal link between a mammalian-like
Fatty Acid Synthase I (FAS-I), a multifunctional enzyme that
conducts de novo synthesis of C16 and C26 fatty acids, and Fatty
Acid Synthase-II (FAS-II) a bacterial-type multi-enzyme complex
that extends FAS-I products to long chain C48–56 fatty acids
termed meromycolic acids. FAS-I derived C26 and meromycolic
acids then undergo a Claisen-type condensation to form mycolic
acids [6,7], a-alkyl b-hydroxy fatty acids which are important and
essential constituents of the mycobacterial cell wall (Figure 2).
KasA and KasB are two distinct ketosynthases that are part of a
core FAS-II complex which also includes a keto-reductase
(FabG1, MabA), a multicomponent dehydratase (Rv0636+
Rv0635 or Rv0637) and an enoyl reductase (InhA) [8,9,10,11,
12,13,14,15,16]. This core complex is involved in a reductive
cycle that elongates an acyl carrier protein (ACP)-bound acyl
chain by iterative addition of two carbons using malonyl-ACP as
a substrate, finally resulting in the formation of a meromycolate
chain.
While kasA is an essential gene in mycobacteria [11], deletion of
Mycobacterium marinum kasB [17] and M. tuberculosis kasB [10]
resulted in viable strains that produced shorter meromycolate
chains and were attenuated in macrophages and mice. In this
study we have examined the whole cell susceptibility of M.
smegmatis and M. tuberculosis to platensimycin. In addition, using
discrete enzymes assays using purified Mt-KasA, Mt-KasB and
Mt-FabH, we have established platensimycin as a promising lead
compound for drug development.
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Results
Whole cell activity of platensimycin against
Mycobacterium smegmatis
Platensimycin has been previously shown to be an effective
inhibitor of Gram-positive bacteria with MIC values as low as
1 mg/ml for S. aureus, E. faecalis and S. pneumoniae [3]. Platensimycin
was initially tested for inhibitory properties against the non-
pathogenic, fast growing M. smegmatis mc2155 which has been used
in a number of studies as a surrogate for M. tuberculosis. The MIC99
of M. smegmatis in liquid medium was found to be 14 mg/ml
(Table 1). We then monitored the growth of M. smegmatis in LB
broth in the presence or absence of 14 mg/ml platensimycin for a
period of 72 hours. While M. smegmatis grew normally in medium
devoid of platensimycin, the culture in the medium containing
platensimycin showed a decrease in OD600 values with time (data
not shown) resulting in clumping after 24 hours of incubation
(Figure 3A). Monitoring of viable colony forming units (CFU)
demonstrated that the culture grown in the presence of
platensimycin possessed a 2 log decrease in CFU (Figure 3B).
The plateau shape observed with the treated cells, rather than a
killing curve, would suggest that platensimycin is bacteristatic in
nature. Further experimentation utilising cells exposed to
platensimycin for 72 hours showed that after washing and re-
inoculation into fresh media, treated cultures could be revived
confirming that the antibiotic is bacteristatic against M. smegmatis.
Activity of platensimycin against slow growing
mycobacteria
To test the antimycobacterial potency of platensimycin against
slow growing mycobacteria we first tested the activity of the
antibiotic against M. tuberculosis CDC1551 and H37Rv. The MIC
of platensimycin required to inhibit the growth of 99% of both M.
tuberculosis strains on solid medium was 12 mg/ml (Table 1)
indicating a comparable potency for this drug against this slow
growing pathogen. Surprisingly, growth of the vaccine strain M.
bovis BCG in the presence of platensimycin was different to that of
M. tuberculosis and the strain grew normally in medium containing
up to 128 mg/ml of platensimycin. In an effort to investigate the
Figure 1. Structure of platensimycin (A) and platencin (B).
doi:10.1371/journal.pone.0006306.g001
Figure 2. Structures of the major mycolic acids of M. tuberculosis and M. smegmatis.
doi:10.1371/journal.pone.0006306.g002
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apparent resistance of BCG to platensimycin we sought to test the
effects of increased membrane permeability by generating a M.
bovis BCG DkasB mutant (Figure 4). It had been previously shown
that a DkasB null mutant in M. tuberculosis synthesised shorter
mycolic acids with almost a complete loss of trans-cyclopropanation
of oxygenated mycolic acids that resulted in increased susceptibil-
ity to lipophilic antibiotics [10]. Interestingly, the M. bovis BCG
DkasB (Table 1) mutant was sensitive to platensimycin (MIC
61 mg/ml) suggesting that the increased permeability in compar-
ison to the parental M. bovis BCG strain has indeed increased the
sensitivity of M. bovis BCG to platensimycin. However the high
MIC of the mutant BCG strain in comparison to that in M.
tuberculosis indicates that it is still unclear whether the resistance of
BCG to platensimycin was solely due to decreased permeability to
the drug.
Platensimycin inhibits biosynthesis of fatty acids and
mycolic acids
To study the biochemical effects of platensimycin treatment,
cultures of M. smegmatis mc2155 were metabolically labelled with
[14C] acetate following exposure to platensimycin. Fatty acids and
mycolic acids were extracted from [14C] labelled cells and
methylated using phase-transfer catalysis and iodomethane.
Extracts of total fatty acid methyl esters (FAMEs) and mycolic
acid methyl esters (MAMEs) from untreated and platensimycin
treated cultures (5–60 mg/ml) were analysed by TLC-autoradiog-
raphy. Biosynthesis of fatty acids and a- and epoxy-mycolic acids
(Figure 2) was significantly inhibited upon platensimycin treatment
(20–40 mg/ml) (Figure 5A). Interestingly, an accumulation of a9-
MAMEs was observed at lower concentrations (10–20 mg/ml) of
platensimycin, similar to studies observed upon treatment of M.
smegmatis with thiolactomycin (TLM), a known inhibitor of KasA
and KasB (Figure 5A) [18]. The inhibition of fatty acids is in
contrast to studies involving the FAS-II inhibitor isoniazid (INH)
where inhibition of mycolic acid biosynthesis leads to an
accumulation of fatty acids [19]. These results suggest that
platensimycin also inhibits fatty acid biosynthesis via inhibition of
mycobacterial FAS-I. Further analysis of the same samples by 2D-
Ag2+ TLC reinforced these findings and revealed more clearly that
synthesis of a (a1 and a2) and epoxy mycolic acids (Figure 6A) was
abolished at lower concentrations, in comparison with the initial
accumulation and then cessation a9-mycolic acid biosynthesis
(Figure 6A). Futhermore, extracts of cell wall bound mycolic acids,
afforded similar profiles upon platensimycin treatment (Figure 6B).
Figure 3. In vivo effect of platensimycin againstM. smegmatis. (A) Clarification of cultures due to clumping and cellular lysis at time point 72 h.
(B) Cultures were grown to an OD600 nm of 0.4 upon which 14 mg/ml of platensimycin was added, samples were take over a 72 h period. Viable counts
were calculated as per the methods where the mean CFU per millilitre from three independent experiments was calculated.$, M. smegmatis;#, M.
smegmatis + platensimycin.
doi:10.1371/journal.pone.0006306.g003
Table 1. Influence of Mt-KasA, Mt-KasB and Mt-FabH
overexpression on platensimycin in whole cell inhibition of M.
tuberculosis, M. smegmatis and M. bovis BCG.
Strain MIC99 (mg/ml)
M. tuberculosis CDC1551 12
M. tuberculosis H37Rv 12
M. smegmatis 14
M. smegmatis pVV16 14
M. smegmatis pVV16-KasA 30
M. smegmatis pVV16-KasB 124
M. smegmatis pVV16-KasAB 126
M. smegmatis pVV16-FabH 16
M. bovis BCG .128
M. bovis BCG pVV16 .128
M. bovis BCG pVV16-KasA .128
M. bovis BCG pVV16-KasB .128
M. bovis BCGDKasB 61
doi:10.1371/journal.pone.0006306.t001
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In addition, analysis of [14C] labelled lipids extracted from
platensimycin-treated cultures also revealed that the synthesis of
mycolate containing lipids glucose monomycolate (GMM) and
trehalose dimycolate (TDM) were reduced (Figure 6C; based on
co-migration with authentic standards). The corresponding
extracts did not show any platensimycin-derived effects on
diacyltrehalose and glycopeptidolipid biosynthesis indicating that
the inhibitory effect of platensimycin was specific to mycolate-
containing glycolipids. These results demonstrated that platensi-
mycin targeted fatty acid and mycolic acid biosynthesis in M.
smegmatis.
Platensimycin resistance of M. smegmatis strains
overexpressing Mt-KasA, Mt-KasB or Mt-FabH
The use of gene overexpression to identify cellular targets of
anti-mycobacterial drugs has been highly successful [20,21,22].
Given that the targets of platensimycin in other bacteria were b-
ketoacyl synthases, we tested the effects of overexpression of Mt-
KasA, Mt-KasB or Mt-FabH on platensimycin resistance in M.
smegmatis. The three b-ketoacyl-ACP synthases, cloned into the E.
coli-Mycobacterium shuttle vector pVV16 were introduced into M.
smegmatis by eletroporation. Multiple copies and constitutive
expression driven by the hsp60 promoter ensures overexpression
of the cloned genes in the host Mycobacterium. First, levels of each
recombinant protein was assessed by western blot to confirm that
any observed change in resistance could be attributed due to
increased levels of the target protein (data not shown). Overex-
pression of Mt-KasA conferred a modest 2-fold increase in
resistance to platensimycin, increasing the MIC from 14 to 30 mg/
ml (Table 1). On the other hand, Mt-KasB overexpression resulted
in a substantial 9-fold increase in the MIC to 124 mg/ml,
respectively (Table 1). A combination of Mt-KasA/B overexpres-
sion failed to substantially enhance resistance to platensimycin
further and possessed a MIC of 126 mg/ml. Interestingly, though
platensimycin had a minimal effect on FabH of other bacteria [2],
overexpression of Mt-FabH in theory should confer a small degree
of resistance to platensimycin but no significant change was
observed (Table 1). These observations were similar to resistance
studies conducted with TLM and strains overexpressing Mt-FabH
[23]. The nine-fold increase in resistance to platensimycin by M.
smegmatis overexpressing Mt-kasB suggests that platensimycin
preferentially targets KasB.
To further confirm the observed effects of overexpression on
MICs, the ability of the recombinant M. smegmatis strains to
incorporate [14C]-acetate into fatty acids and mycolic acids was
examined. TLC analysis of FAMEs and MAMEs extracted from
different strains treated with platensimycin revealed that whilst
mycolic acid biosynthesis was only partially restored in the Mt-
KasA overproducing strain, overexpression of either Mt-KasB or
Mt-KasAB fully restored fatty acid and mycolic acid biosynthesis
(Figure 5 B–D).
Activity of platensimycin against M. tuberculosis b-
ketoacyl-ACP synthases and FAS-I
To evaluate the effect of platensimycin on in vitro enzymatic
activity, the impact upon [14C] malonate incorporation into fatty
acids in cell free extracts of M. smegmatis enriched with FAS-I, and
either purified Mt-KasA, Mt-KasB or Mt-FabH was assessed in
discrete assays as described earlier [13,21,24]. In these assays
[14C]malonyl-CoA is transacylated to AcpM via mtFabD prior to
the addition of the relevant substrates (C16-AcpM and C16-CoA)
and the enzyme of interest. Upon completion and termination of
the experiment the radiolabelled acyl derivates are extracted using
organic solvents. The assay was performed with a titre of
platensimycin present in triplicate. The results were formulated
into a graph where the 50% activity was calculated and noted as
the IC50. Platensimycin was active against both Mt-KasA and Mt-
KasB possessing IC50 values of 2 mg/ml (4.53 mM) and 4.2 mg/ml
(9.51 mM), respectively (Table 2). These results are consistent with
the in vitro inhibition of S. aureus FabF and E. coli FabF by
Figure 4. Generation of a M. bovis BCG kasB null mutant. Maps of the kasB region in the M. bovis BCG genome and its corresponding region in
the conditional mutant DkasB are shown on the left, with the corresponding Southern blot on the right. The regions used as porbes are indicated by
solid lines with square ends while the expected bands are indicated by broken lines (with sizes indicated). hyg, hygromycin resistance gene from
Streptomyces hygroscopicus; res, cd resolvase recognition sites.
doi:10.1371/journal.pone.0006306.g004
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Figure 5. TLC-autoradiography of FAMEs and MAMEs from M. smegmatis strains overexpressing Mt-KasA, Mt-KasB and Mt-FabH
following platensimycin treatment. Platensimycin (0–60 mg/ml) was titred into M. smegmatis cultures at an OD600 nm of 0.4 prior to labelling with
1 mCi/ml [1,2-14C]acetate for 12 h. [14C]-FAMEs and MAMEs were extracted and resolved by TLC. An equivalent aliquot of the resulting solution of
FAMEs and MAMEs was subjected to TLC using silica gel plates developed twice in petroleum ether-acetone (95:5). Autoradiograms were produced
by overnight exposure to Kodak X-Omat film to reveal [14C]labeled FAMEs and MAMEs. (A) M. smegmatis pVV16, (B) M. smegmatis pVV16-Mt-KasA, (C)
M. smegmatis pVV16-Mt-KasB, and (D) M. smegmatis pVV16-Mt-KasAB.
doi:10.1371/journal.pone.0006306.g005
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platensimycin [2]. Interestingly, the IC50 values obtained with
platensimycin are significantly lower than those obtained with
another mycobacterial KAS inhibitor TLM (KasA = 20 mM, KasB
90 mM) [25]. While studies by Wang et al. [2] demonstrated that S.
aureus FabH activity was inhibited by platensimycin (IC50 =
67 mM), consistent with our overexpression studies, Mt-FabH
activity was insensitive to platensimycin (IC50.150 mg/ml,
340 mM) in comparison to Mt-KasA and Mt-KasB (Table 2).
Interestingly, when crude cell free extracts of either M. smegmatis
or the related C. glutamicum [26] were assayed for FAS-I activity,
platensimycin inhibited FAS-I activity at an IC50 value of 12 mg/
ml and 6.5 mg/ml, respectively (Table 2).
Comparisons of in silico models of platensimycin-bound
ketosynthases
Despite only a moderate level of sequence identity (,36%)
between Mt-KasB and E. coli FabF, the two enzymes display
identical folds (Suppl. Figure 1A). To ascertain whether the active
site of Mt-KasB would be compatible with the steric requirements of
platensimycin, we generated a hypothetical structural model of
platensimycin-bound Mt-KasB (Suppl. Figure 1B, C). Utilising the
Mt-KasB (PDB code 2GP6) superposition with platensimycin-
bound Ec-FabF (PDB code 2GFX). Subsequent conjugate-gradient
energy minimization relieved mild steric clashes between protein
and ligand and resulted, compared to ligand-free Mt-KasB, in
minor to moderate shifts of side chains located within a 4 A˚-radius
of platensimycin (root mean square displacement 0.93 A˚ for 186
main and side chain atoms, maximum displacement 3.5 A˚).
The model illustrates steric compatibility between platensimycin
and the active site of Mt-KasB, but hints at subtle differences in
Figure 6. TLC-autoradiography of M. smegmatis lipid extracts and cell wall bound mycolates following platensimycin treatment.
Platensimycin (0, 20, 30, 40 mg/ml) were added to M. smegmatis cultures at an OD600 nm of 0.4 for 8 h prior to labelling with 1 mCi/ml [1,2-
14C]acetate
for 12 h. (A) 2D-Ag2+ TLC using silica gel plates developed twice in hexane-ethyl acetate (95:5) (direction I) then thrice in petroleum ether-diethyl
ether (85:15) (direction Ag II). (B) Cell wall bound mycolate profiles were revealed following two developments in petroleum ether-acetone (95:5). (C)
[14C]-Apolar lipids were extracted and resolved by TLC; direction 1, chloroform-methanol-water (100:14:0.8); direction 2, chloroform-acetone-
methanol-water (50:60:2.5:3). DAT; diacyltrehalose, GMM; glucose monomycolate, TDM; trehalose dimycolate. Autoradiograms were produced by
overnight exposure to film to reveal [14C]-labelled lipids.
doi:10.1371/journal.pone.0006306.g006
Table 2. In vitro inhibition (IC50) of platensimycin against Mt-
KasA, Mt-KasB, Mt-FabH and Ms-FAS-I and Cg-FAS-I.
IC50 (mg/ml)
Mt-KasA 2 (0.1)
Mt-KasB 4.2 (0.1)
Mt-FabH .150
Ms-FAS-I 12 (0.1)
Cg-FAS-I 6.5 (0.2)
Figures in brackets represent calculated standard error.
doi:10.1371/journal.pone.0006306.t002
Platensimycin and Mycobacteria
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protein-inhibitor interactions between Ec-FabF and Mt-KasB.
The benzoic acid ring faces a structural environment that is
virtually identical to that in Ec-FabF (Suppl. Figure 1B). However,
the ketolide group would appear to be less exposed to solvent than
it is in the Ec-FabF:platensimycin complex (Figure S1 B,C).
Indeed, the simulated complex structure suggests that the ketolide
group makes close hydrophobic interactions with Met212 and
Ile214 (Figure S1 B,C), contacts that are not seen in platensimycin-
bound Ec-FabF, where these residues correspond to alanine side
chain. Such differences provide scope for design efforts with the
aim to enhance inhibitor affinity in a species-specific manner.
Discussion
Mycolic acid biosynthesis is essential for mycobacterial survival
and many antituberculosis drugs like isoniazid, ethionamide and
thiolactomycin target enzymes of this exclusive pathway [8,21].
The identification and functionality of novel lead antitubercular
agents are essential in the present times due mainly to the
emergence of MDR-TB [27] and more recently, XDR-TB [28].
In this worrying climate where untreatable strains of XDR-TB
may become apparent the impetus for the discovery of new anti-
tubercular agents becomes crucial. The discovery and character-
ization of new drugs targeting key enzymes involved in essential
mycobacterial biosynthetic pathways is paramount but without the
introduction of novel lead compounds, such as platensimycin
antitubercular therapy will not proceed fast enough to cope with
the increasing resistance observed today. Not only should drug
development focus on the synthesis of active analogues of existing
anti-mycobacterials, but also on identification of new classes of
drugs, such as platensimycin.
Platensimycin, a natural product produced by Streptomyces
platensis represents a new chemical class of antibiotics [3]. In this
study we have shown that platensimycin is active against M.
tuberculosis and through the use of the M. smegmatis surrogate system
we were able to investigate and elucidate the mode of action of
platensimycin against Mycobacterium spp. We observed inhibition of
both mycobacterial FAS-I and FAS-II in vitro in cell free assays and
resultant inhibition of both fatty acid and mycolic acid biosynthesis
in whole cells treated with the antibiotic. Although, in Mycobac-
terium the fatty acyl-products of FAS-I provide primers for
extension to meromycolate precursors of mycolic acids, the effects
on FAS-II appear to be more complex than a simple deprivation of
primer supply brought about via FAS-I inhibition. Therefore the
combination of activity observed against both FAS-I and the FAS-
II components KasA/KasB contributed to the inhibitory effect of
platensimycin against M. smegmatis.
While from the point of view of drug development FAS-II
inhibition, which causes cessation of the essential mycolic acids, is
desirable, inhibition of FAS-I is not since mammalian fatty acid
synthases are similar to FAS-I. Indeed, human and rat FAS-I were
found to be inhibited in vitro by platensimycin [29]. However,
platensimycin does not have the same effect when used on whole
cells as it was previously demonstrated by the patent applicants
Wang et al. [3] that platensimycin had low mammalian cell toxicity
(IC50 of HeLa MTT .1000 mg/ml). Additionally, the authors also
confirmed a lack of antifungal activity against Candida albicans which
synthesises fatty acids via a type I fatty acid synthase (.64 mg/ml).
Furthermore, our own studies with the related C. glutamicum, showed
that while corynebacterial FAS-I activity was inhibited in vitro
(Table 2), platensimycin failed to inhibit growth of cultures of C.
glutamicum (data not shown). These findings suggested that, contrary
to data obtained with in vitro inhibition assays with eukaryotic FAS-I,
platensimycin selectively inhibits mycobacterial FAS-II in vivo.
Previous studies by Wang et al. [2] demonstrated that
platensimycin poorly inhibited FabH in other bacteria. Interest-
ingly, it was shown that platencin (Figure 1B) a related antibiotic
was more active against S. aureus FabH (9.17 mM). Both
platensimycin and platencin are structurally similar. Platensimycin
contains a pentacyclic motif with a cyclic ether ring, whereas
platencin contains a unique tetracyclic motif without the ether ring
[2]. The chemical modification between platensimycin and
platencin has been proposed to be responsible for the change in
activity in S. aureus FabH. While platensimycin failed to inhibit
mycobacterial Mt-FabH, it would be interesting to examine
whether platencin is active against Mt-FabH. Altogether, the
culture inhibition studies and in vitro assay data indicate that
platensimycin targets Mt-KasA and Mt-KasB. Given that
overexpression of Mt-KasA or Mt-KasB increased the MIC of
the host M. smegmatis strain for platensimycin, it was surprising that
platensimycin was relatively inactive against M. bovis BCG. Poor
permeability may have been one of the factors responsible for the
observed resistance. Indeed, deletion of kasB from M. bovis BCG
resulted in a strain which was more permeable to lipophilic
antibiotics [10] and thus sensitive to platensimycin (Table 1).
However, it remains unclear whether poor permeability was the
sole factor responsible for the resistance of BCG to the antibiotic.
This data also suggests that in order to realise the full potential of
this compound as an anti-tuberculosis agent, it is imperative that
any future modifications to platensimycin include designs that
render it more diffusible into the lipid-rich envelope of
mycobacteria. Futhermore, in silico modelling of platensimycin-
bound Mt-KasB suggested novel molecular interactions that were
not seen in platensimycin-bound Ec-FabF. Such differences
provide scope for design efforts with the aim to enhance inhibitor
affinity in a species-specific manner. Our results highlight the
potential of platensimycin as an inhibitor of the essential fatty acid
and mycolic acid biosynthesis pathways in mycobacteria.
Materials and Methods
Plasmids, strains and DNA manipulation
The Escherichia coli-mycobacteria shuttle vector pVV16 (a gift
from Varalakshmi Vissa, Colorado State University, CO, USA)
containing the hsp60 promoter and encoding a 6-histidine C-
terminal tag was used for the over-expression of Mt-KasA and Mt-
KasB. Mt-kasA PCR amplification was performed using the
upstream primer 59-gatcgatcaagcttgatgagtcagccttccaccg-39 and the
downstream primer 59-gatcgatcaagcttgtaacgcccgaaggcaagc-39,
which contain HindIII and HindIII restriction sites, respectively
(underlined). The 1251 bp PCR product was then digested with
HindIII and ligated with similarly digested pVV16, giving rise to
pVV16-Mt-KasA. Mt-kasB was cloned similarly using the
upstream primer 59-gatcgatccatatggatgggggtccccccgctt-39 and the
downstream primer 59-gatcgatcaagcttgtaccgtccgaaggcgat-39,
which contain NdeI and HindIII restriction sites, respectively
(underlined). The 1317 bp PCR product was then digested with
NdeI and HindIII and ligated with similarly digested pVV16,
giving rise to pVV16-Mt-KasB. Mt-FabH was cloned similarly
using the upstream primer 59-gatcgatccatatggtaccgtccgaaggcgat-39
and the downstream primer 59-gatcgatcaagcttacccttcggcattcgca-39,
which contain NdeI and HindIII restriction sites, respectively
(underlined). The 1033 bp PCR product was then digested with
NdeI and HindIII and ligated with similarly digested pVV16,
giving rise to pVV16-Mt-FabH. The pVV16-KasAB was con-
structed using the Mt-kasA upstream primer and the Mt-kasB
downstream primer, the 2623 bp PCR product was then digested
with NdeI and HindIII and ligated with similarly digested pVV16,
Platensimycin and Mycobacteria
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giving rise to pVV16-Mt-KasAB. The kasB-knockout phage
phAE404 [10] was utilized to construct a kasB deletion in M.
bovis BCG. Specialized transduction was performed as described in
Bardarov et al. [30]. The validity of the M. bovis BCGDkasB was
confirmed by Southern blot analysis (Figure 4). The coding
sequences of all the recombinant genes were verified by DNA
sequencing.
Whole cell effects of platensimycin on Mycobacterium
spp
M. tuberculosis CDC1551 was grown in 7H9 broth supplemented
with 10% OADC enrichment and 0.05% Tween-80 to OD600 of
0.4. Following serial 10 fold dilutions, 20 ml of each dilution was
spotted on 7H10 agar plates containing 0–128 mg/ml platensimy-
cin. The minimum concentration of platensimycin required to
inhibit growth of single colonies was noted as the minimum
inhibitory concentration (MIC).
M. smegmatis-pVV16 and overexpression strains were grown in
Luria-Bertani Broth (LB) (Difco) with 25 mg/ml kanamycin and
0.05% Tween 80 at 37uC to an optical density of 600 nm (OD600)
of 0.25. A 10 ml culture was aliquoted and platensimycin added at
the MIC of 15 mg/ml. The OD600 was recorded over 72 h and
100 ml samples were taken periodically and stored at 4uC for
viable count analysis. After 72 h the cells were pelleted by
centrifugation and washed with 8 ml of PBS buffer to remove
platensimycin and the pellet resuspended in fresh LB media. The
OD was recorded over 55 h and 100 ml samples taken and viable
counts determined at each time point [31]. Briefly, the 100 ml
samples were serially diluted to 1027 and 10 ml samples, in
triplicate, were spotted on to LB selective agar thrice. Following
incubation at 37uC, the colonies were counted and converted into
colony forming units (CFU) (CFU/ml). The MIC99 of platensi-
mycin against M. smegmatis and M. bovis BCG were calculated by
Alamar Blue testing as previously described [32]. Briefly, 200 ml of
sterile deionized water was added to all outer-perimeter wells of a
sterile 96-well plate (Corning Incorporated, Corning, NY, USA) to
minimize evaporation of the medium in the test wells during
incubation. The wells in rows B to G in columns 3 to 11 received
100 ml of 7H9 medium containing 25 mg/ml kanamycin, 50 mg/
ml hygromycin and ADC (Beckton Dickinson, Sparks, MD).
Platensimycin was added to rows B–G followed by 1:2 serial
dilutions across the plate to column 10, and 100 ml of excess
medium was discarded from the wells in column 10. A bacterial
culture (100 ml) was added to the wells in rows B to G in columns 2
to 11, where the wells in column 11 served as drug-free controls.
The plates were sealed with parafilm and were incubated at 37uC
for 24 h for M. smegmatis strains or 5 days for M. bovis BCG strains.
A freshly prepared 1:1 mixture of Alamar Blue (Celltiter-BlueTM,
Promega Corp, Madison, WI, USA) reagent and 10% TweenH 80
(50 ml) were added to well B11. The plates were reincubated at
37uC for 24 h. The cell viability assay was carried out as per the
manufacturer’s protocol followed by MIC99 calculations.
Determination of the in vivo effects of platensimycin on
cell envelope lipid synthesis
M. smegmatis cultures were grown to an OD600 nm of 0.4 in the
presence of 0.25% Tween 80 in Sautons medium at 37uC.
Platensimycin was added at various concentrations followed by
incubation at 37uC for 16 h for M. bovis BCG and 8 h for M.
smegmatis at which point 1 mCi/ml [1,2-14C]acetate (57 mCi/
mmol, GE Healthcare, Amersham Bioscience) was added to the
cultures. The M. bovis BCG and M. smegmatis cultures were further
incubated at 37uC for 24 h and 12 h, respectively. The [14C]
labelled cells were harvested by centrifugation at 20006g, washed
with PBS and processed as described below.
The [14C] labelled cells were initially resuspended in CH3OH/
0.3% NaCl (2 ml, 100:10, v/v) and mixed with 1 ml of petroleum
ether (60–80uC) for 15 min. The upper petroleum ether layer was
removed and a further 1 ml of petroleum ether added, followed by
further mixing for 15 min. The petroleum ether extracts were
combined and evaporated under nitrogen using a heating block.
The dried apolar lipid extract was resuspended in 200 ml of
CH2Cl2 prior to thin-layer chromatography (TLC) and autoradi-
ography [33]. Polar lipids were extracted by the addition of
CHCl3/CH3OH/0.3% NaCl (2.3 ml, 9:10:3, v/v/v) to the lower
methanolic saline phase and mixed for 1 h. The mixture was
centrifuged and the pellet re-extracted twice with CHCl3/
CH3OH/0.3% NaCl (750 ml, 5:10:4, v/v/v). CHCl3 (1.3 ml)
and 0.3% NaCl (1.3 ml) were added to the combined extracts and
the mixture centrifuged. The lower layer containing the polar
lipids recovered and dried. The polar lipid extract was
resuspended in CHCl3/CH3OH (2:1, v/v). The apolar lipid
extract (50,000 cpm) was applied to the corners of 6.666.6 cm
plates of silica gel 60 F254 (Merck 5554) TLC plates. The plates
were then developed using direction 1, chloroform-methanol-
water (100:14:0.8, v/v/v) and direction 2, chloroform-acetone-
methanol-water (50:60:2.5:3, v/v/v/v) to separate [14C]-labelled
lipids (TDM and glucose monomycolate [GMM]). Lipids were
visualized by autoradiography by overnight exposure of Kodak X-
Omat AR film to the TLC plates to reveal [14C]labelled lipids and
compared to know standards [33].
Determination of the in vivo effects of platensimycin on
mycolic acid synthesis
The delipidated cells and whole cell pellets were similarly
subjected to alkaline hydrolysis using 5% aqueous tetrabutylammo-
nium hydroxide (TBAH) at 100uC overnight, followed by the
addition of 4 ml of CH2Cl2, 500 ml of CH3I, 2 ml of water, followed
by mixing for 30 min. The upper aqueous phase was discarded
following centrifugation and the lower organic phase washed thrice
with water and evaporated to dryness. The resulting FAMEs and
MAMEs were dissolved in diethyl ether and insoluble residues
removed by centrifugation. The etheral solution was evaporated to
dryness and re-dissolved in 200 ml of CH2Cl2. Equivalent volumes
of the resulting solution of FAMEs and MAMEs were subjected to
TLC using silica gel plates (5735 silica gel 60F254; Merck,
Darmstadt, Germany), developed in petroleum ether-acetone
(95:5). Autoradiograms were produced by overnight exposure of
Kodak X-Omat AR film to the plates to reveal [14C]-labelled
FAMEs and MAMEs. Ag2+-TLC was performed as described
previously using Ag2+-impregnated TLC plates developed twice in
direction I, hexane-ethyl acetate (95:5, v/v), and then thrice in
direction II, petroleum ether-acetone (85:15, v/v) [34].
Determination of the in vitro effects of platensimycin
using crude cell-free extracts and purified proteins Mt-
KasA, Mt-KasB and Mt-FabH
FAS-I extracts from M. smegmatis and C. glutamicum were
prepared as described previously [35]. FAS-I experiments were
conducted as described [18] using the 40–80% ammonium sulfate
fraction [34]. Briefly, platensimycin was titred (0.1–150 mg/ml)
into the standard reaction as follows: 100 mM potassium
phosphate pH 7.0, 5 mM EDTA, 5 mM dithiothreitol, 300 mM
acetyl-CoA, 100 mM NADPH, 100 mM NADH, 1 mM flavin
mononucleotide, 500 mM a-cyclodextrin, 20 mM malonyl-CoA,
100,000 cpm of [2-14C] malonyl-CoA, and 100 ml of the cytosolic
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enzyme preparation (1 mg of protein) in a total volume of 500 ml.
Reactions were performed in triplicate at 37uC for 1 h and
terminated by the addition of 500 ml of 20% potassium hydroxide
in 50% methanol at 100uC for 30 min. Following acidification
with 300 ml of 6 M HCl, the resultant [14C]-labelled fatty acids
were extracted three times with petroleum ether. The organic
extracts were pooled, washed once with an equal volume of water,
and dried in a scintillation vial prior to scintillation counting using
5 ml of EcoScintA (National Diagnostics, Hull, U.K.).
Mt-KasA, Mt-KasB and Mt-FabH proteins were purified and
assayed as described previously [21,24]. Briefly, platensimycin was
titred (0.1–150 mg/ml) into the standard reaction as follows; Holo-
AcpM (40 mg) was incubated on ice for 30 min with b-
mercaptoethanol (0.5 mmol) in a total volume of 40 ml.
[2-14C]malonyl-CoA (100, 000 cpm, 6.78 nmol, 1.66 kBq; Amer-
sham), Mt-FabD (40 ng) and 25 ml of 1 M potassium phosphate
buffer, pH 7.0, were added followed by incubation at 37uC for
30 min. C16-AcpM/holo-AcpM heterogeneous mix (22.5 mg) was
added to obtain a final volume of 89 ml. Mt-KasA or Mt-KasB
(0.25 mg) was added to initiate the reaction and was held at 37uC
for 1 h. The reaction was quenched by the addition of 2 ml of a
NaBH4 reducing solution (5 mg/ml NaBH4 in 0.1 M K2HPO4,
0.4 M KCl and 30% (v/v) THF). The reaction was held at 37uC
for a further 1 h followed by two extractions with 2 ml of water-
saturated toluene. The combined organic phases were pooled and
washed using 2 ml of toluene-saturated water. The organic layer
was removed and dried under a stream of nitrogen in a
scintillation vial. The [14C18]-1,3-diol product was then quantified
by liquid scintillation counting using 5 ml of EcoScintA (National
Diagnostics, Hull, UK).
The activity of Mt-FabH was determined as previously
described [24]. Platensimycin was titred (0.1–150 mg/ml) into
the standard reaction as follows. The assays contained 50 mM
holo-ACP/AcpM, 1 mM b-mercaptoethanol, 0.1 M sodium
phosphate buffer, pH 7.0, 50 mM malonyl-CoA, 45 nCi of
[2-14C]malonyl-CoA (100, 000 cpm, 6.78 nmol, 1.66 kBq; Amer-
sham), 12.5 mM acyl-CoA primer, and Mt-FabD (0.3 mg of
protein) in a volume of 50 ml and incubated at 37uC for 30 min.
The reaction was initiated by the addition of 0.5 mg of Mt-FabH
followed by incubation at 37uC for 40 min. The Mt-FabH assays
were quenched and processed as described earlier for the Mt-
KasA/B assays.
Supporting Information
Figure S1
Found at: doi:10.1371/journal.pone.0006306.s001 (1.05 MB
DOC)
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